Navigation Links
Antidepressant use associated with increased mortality among critically ill patients?
Date:5/22/2012

ATS 2012, SAN FRANCISCO Researchers at Beth Israel Deaconess Medical Center, in Boston, and the Massachusetts Institute of Technology in Cambridge, have found that critically ill patients were more likely to die if they were taking the most commonly prescribed antidepressants when they were admitted to the intensive care unit (ICU).

The researchers conducted a retrospective study using the electronic medical records of 10,568 patients to look at in-hospital mortality and mortality a year after being admitted to the ICU.

"We found that mortality was higher overall for patients taking antidepressants prior to admission to the ICU and remained significantly higher a year later," said Katherine. M. Berg, MD, one of the physicians involved in the study. "We also found that certain subgroups of patients, particularly patients admitted for cardiac problems, appeared to be at even greater risk."

The study results will be presented at the ATS 2012 International Conference in San Francisco.

Of the 10,568 patient records studied, 1,876 patients were taking either a selective serotonin reuptake inhibitor (SSRI) or a serotonin and norepinephrine reuptake inhibitor (SNRI) prior to admission to an ICU. They were compared to patients admitted to an ICU who were not on one of these medications. After adjusting for age, gender, ICD-9 diagnosis, disease severity and co-morbidities, the researchers found that patients on SSRI/SNRI's prior to admission to the ICU were 73 percent more likely to die in the hospital (p<0.001), and that the increase in risk persisted at one year.

Among patient groups, risk was highest among patients with acute coronary syndrome and those who had undergone cardiac surgery. For both of these patient groups, the risk of dying in the hospital was more than double if they were taking one of these antidepressants prior to admission (OR 2.41; p<.0020 and 2.08; p<0.001, respectively).

Not all patient groups demonstrated that patients
'/>"/>

Contact: Nathaniel Dunford
ndunford@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Antidepressants in Pregnancy May Delay Developmental Milestones
2. A new generation of rapid-acting antidepressants?
3. Kids Suicide Risk Same for All Antidepressants
4. Antidepressants May Ease Damage From Stroke
5. Antidepressants May Improve Heart Health
6. No One Antidepressant Raises Suicide Risk More Than Others
7. Antidepressants in pregnancy increase risk of miscarriage
8. Certain Popular Antidepressants Linked to Cataracts in Seniors
9. Autism: Lack of evidence for antidepressants
10. Decrease in suicide not linked to newer antidepressants
11. Antidepressant Use Rising as Psychotherapy Rates Fall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Bunion Bootie, the newest and ... an early celebration of the early holiday shopping season. ... at the promotional price of $29.95 each (normally $33.95 ... to any automatic discounts applied when buying more than ... for complete details. It’s simple: purchasing more Bunion ...
(Date:11/26/2014)... November 26, 2014 News Facts ... expanded capabilities at RSNA 2014 in Chicago. The ... and share diagnostic images, photos, videos and documents ... booth #8107 will learn more about these innovative ... technologies and partner initiatives – that enable more ...
(Date:11/26/2014)... who enter puberty early are at increased risk for ... linked with a number of factors associated with depression, ... to the researchers. Early puberty was also linked to ... and having friends who were prone to getting into ... an association between early puberty and these factors, it,s ...
(Date:11/26/2014)... -- The number of emergency department visits in the United ... record 136 million in 2011, according to the U.S. Centers ... that fewer people were going to ERs with non-urgent medical ... care within two hours of arriving at the ER. In ... Sixty percent of patients arrived at the ER after ...
(Date:11/26/2014)... Randy Dotinga HealthDay ... Heartburn drugs such as Prilosec and Nexium may disrupt the ... risk of infections and other problems, a small new study ... make it more likely users will become ill, and study ... pump inhibitors. However, these antacids "should be used at ...
Breaking Medicine News(10 mins):Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:ER Visits on the Rise, Study Reports 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3
... mass, but long-term effects on vitality unclear, scientists say ... experimental drug can restore the amounts of muscle-linked growth ... shows. , Those on the therapy also gained muscle ... no clear indication that this led to significant improvements ...
... percent versus third quarter last year ... 4:30 p.m. Eastern Time Today, IRVINE, Calif., Nov. 6 ... intravascular temperature,management (IVTM(TM)) therapies for critically ill patients, today reported,on ... and,nine months ended September 30, 2008., Revenue for the ...
... Company Delivers First Month of Positive Gross Profits ... Corporation,(Nasdaq: PODD ), the leader in patch pump ... results for the three,and nine months ended September 30, ... $10.1 million compared to,$3.8 million in the third quarter ...
... November 06, 2008 Down syndrome, the most ... 1-in-700 births in the United States. Additionally, nearly 80 ... birth. , The Centers for Disease Control (CDC), in ... meeting of experts to review the current knowledge of ...
... STEWARTVILLE, Minn., Nov. 6 Rochester Medical,Corporation (Nasdaq: ... and year ended September 30, 2008., The Company ... to $8,437,000 for the fourth quarter of last year. ... $.03 per diluted share,compared to $733,000 or $.06 per ...
... ... Expectations, DENVER, Nov. 6 Air Methods ... 2008.,Revenue increased 32% to $133.8 million from $101.5 million in the year-ago,quarter. ... million in the prior-year nine-month period., For the quarter, net income ...
Cached Medicine News:Health News:Drug Boosts Natural Growth Hormone in Seniors 2Health News:Drug Boosts Natural Growth Hormone in Seniors 3Health News:Drug Boosts Natural Growth Hormone in Seniors 4Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 2Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 3Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 4Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 5Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 6Health News:Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress 7Health News:Insulet Reports Third Quarter 2008 Results 2Health News:Insulet Reports Third Quarter 2008 Results 3Health News:Insulet Reports Third Quarter 2008 Results 4Health News:Insulet Reports Third Quarter 2008 Results 5Health News:Insulet Reports Third Quarter 2008 Results 6Health News:Insulet Reports Third Quarter 2008 Results 7Health News:Insulet Reports Third Quarter 2008 Results 8Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 2Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 3Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 4Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 5Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 6Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 7Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 8Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 2Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 3Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 4Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 5Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 6Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 7
(Date:11/26/2014)... November 26, 2014 Investor-Edge has initiated ... VVUS ), Horizon Pharma PLC (NASDAQ: HZNP ), ... (NYSE: JNJ ), and Theravance Inc. (NASDAQ: ... be accessed at: http://investor-edge.com/register . On Tuesday, ... 0.07%, the Dow Jones Industrial Average edged 0.02% lower, to ...
(Date:11/26/2014)... , Inc. (NASDAQ: BIOS ) announced today that ... at the Bank of America Merrill Lynch 2014 Leveraged Finance Conference ... , Wednesday, December 3, 2014 , , , , Time: ... Location: , , , Boca Raton Resort and Club, Florida , ... BioScrip, Inc. is a leading national provider of infusion and ...
(Date:11/26/2014)... 26, 2014 Zynerba Pharmaceuticals , Inc., ... innovative transdermal synthetic cannabinoid treatments, today announced that the ... Healthcare Conference 2014. The conference will be held December ... New York . Zynerba,s Chairman and ... pm on Tuesday, December 2. To listen ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
... The U.S. Health and Human ... has selected Thomson Reuters to develop a secure, ... comparative effectiveness studies without the need for professional ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090507/NY12658LOGO ) ...
... 14 The U.S. Food and Drug Administration ... chelation products are unapproved drugs and devices and ... to make unproven claims about these products. There ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo:   ...
Cached Medicine Technology:Federal Government Selects Thomson Reuters to Build Tool That Streamlines Comparative Effectiveness Research 2FDA Issues Warnings to Marketers of Unapproved 'Chelation' Products 2FDA Issues Warnings to Marketers of Unapproved 'Chelation' Products 3FDA Issues Warnings to Marketers of Unapproved 'Chelation' Products 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: